New attack on stubborn lung cancer: zap tumors, then boost immunity
NCT ID NCT04892953
Summary
This study is for people with stage III non-small cell lung cancer that has started to grow again (progressed) after their initial chemo-radiation and immunotherapy. It tests whether using targeted treatments like surgery or radiation to attack specific progressing tumors, followed by continued immunotherapy (durvalumab), can help control the cancer for longer. The goal is to see if this combined strategy can delay the cancer from getting worse and help patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.